Hosted on MSN
FDA Approves Johnson & Johnson’s TREMFYA for Pediatric Psoriasis and Psoriatic ArthritisHORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved TREMFYA® (guselkumab) for children six years and older weighing at least 40 kilograms with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results